Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000162828023001868/nvo-20221231.htm
December 2023
November 2023
November 2023
November 2023
November 2023
November 2023
November 2023
November 2023
November 2023
November 2023
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000162828023001868/nvo-20221231.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Novo Nordisk A S.
Novo Nordisk A S's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 20-F Annual Report
Material Contracts, Statements, Certifications & more
Novo Nordisk A S provided additional information to their SEC Filing as exhibits
Ticker: NVO
CIK: 353278
Form Type: 20-F Annual Report
Accession Number: 0001628280-23-001868
Submitted to the SEC: Wed Feb 01 2023 7:53:07 AM EST
Accepted by the SEC: Wed Feb 01 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations